Monash IVF Group earnings: FY26 profit slips, outlook improves

The Monash IVF Group Ltd (ASX: MVF) share price is in focus as the company posts FY26 revenue of $269.5 million and declares a final fully franked dividend, despite a 41% fall in underlying net profit after tax (NPAT).

What did Monash IVF Group report?

• Revenue of $269.5 million, down 0.9% from FY25
• Underlying EBITDA of $53.4 million, down 19.5%
• Underlying NPAT of $16.1 million, down 41.2%
• Reported EBITDA of $43.5 million; reported NPAT of $8.3 million
• Final fully franked FY26 dividend of 1.3 cents per share, total FY26 dividends of 2.5 cents (payout ratio 60%)
• Net operating cash flow of $36.7 million (up from $12.9 million in FY25)

What else do investors need to know?

Monash IVF faced a challenging start to FY26, with domestic stimulated cycle volumes softening in the first half. However, momentum improved in the second half, and market share climbed to 20.2%. The company’s international and genetics divisions delivered record results, with offshore revenue rising 15%, and strong growth in specialist genetics testing.

The group focused on strengthening its medical workforce, refreshing leadership, and investing in major infrastructure. Capital expenditure for the year reached $23.8 million, supporting projects like the new Brisbane fertility clinic and increased surgical capacity in Victoria.

What did Monash IVF Group management say?

Speaking about the results, Monash IVF’s CEO, Dr Victoria Atkinson, said:

FY26 was a year of two halves for Monash IVF. While the first half was challenging, we exited the year with improving momentum, with domestic stimulated cycle volume trends strengthening, market share increasing through the second half and our international businesses delivering record performance.

We have used FY26 to strengthen the foundations of the business—building our medical workforce, strengthening leadership and governance, completing significant infrastructure investment and commencing a structural productivity program. We have also launched Nurture 2030, our three-year strategy to accelerate sustainable growth and create stronger returns.

We enter FY27 with multiple growth engines strengthened and a clear focus on execution: growing domestic stimulated cycle volumes, expanding market share, unlocking our completed capital investments, improving productivity and continuing to scale International, Genetics and Diagnostics. With the foundations now in place, Monash IVF is positioned to convert volume growth into stronger earnings through operating leverage and strategic execution.

What’s next for Monash IVF Group?

Looking to FY27, Monash IVF expects stronger financial performance as market conditions improve and expansion efforts take hold. Key priorities include connecting patient journeys with better data, expanding clinical specialties, and embedding ongoing productivity gains.

The group aims to reduce capital expenditure by 50% and reignite organic growth in key states like Victoria and NSW. Management also notes Monash IVF’s strong governance will help it efficiently implement new industry regulations, supporting future returns.

Monash IVF Group share price snapshot

The Monash IVF share price has underperformed the S&P/ASX 200 index (ASX: XJO) over the past 12 months with a decline of around 4%.

View Original Announcement

The post Monash IVF Group earnings: FY26 profit slips, outlook improves appeared first on The Motley Fool Australia.

More reading

• Strike Energy posts project breakthrough, secures West Erregulla funding
• Bell Potter says this ASX healthcare share could rise 200%+
• Wildcat Resources delivers more high-grade lithium drill results
• 3 ASX dividend shares raising dividends like clockwork
• Liontown FY26 results: Maiden profit, record revenue as lithium prices rebound

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.